These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 25267746)

  • 21. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group.
    Spunt SL; Smith LM; Ruymann FB; Qualman SJ; Donaldson SS; Rodeberg DA; Anderson JR; Crist WM; Link MP
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6072-9. PubMed ID: 15447992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group.
    Casey DL; Chi YY; Donaldson SS; Hawkins DS; Tian J; Arndt CA; Rodeberg DA; Routh JC; Lautz TB; Gupta AA; Yock TI; Wolden SL
    Cancer; 2019 Sep; 125(18):3242-3248. PubMed ID: 31174239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group.
    Wolden SL; Lyden ER; Arndt CA; Hawkins DS; Anderson JR; Rodeberg DA; Morris CD; Donaldson SS
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1071-6. PubMed ID: 26581144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology Group.
    Walterhouse DO; Meza JL; Breneman JC; Donaldson SS; Hayes-Jordan A; Pappo AS; Arndt C; Raney RB; Meyer WH; Hawkins DS
    Pediatr Blood Cancer; 2011 Jul; 57(1):76-83. PubMed ID: 21298768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study.
    Breneman J; Meza J; Donaldson SS; Raney RB; Wolden S; Michalski J; Laurie F; Rodeberg DA; Meyer W; Walterhouse D; Hawkins DS
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):720-6. PubMed ID: 22104356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
    Gupta AA; Anderson JR; Pappo AS; Spunt SL; Dasgupta R; Indelicato DJ; Hawkins DS
    Cancer; 2012 Feb; 118(4):1130-7. PubMed ID: 21761400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Intergroup Rhabdomyosarcoma Study-II.
    Maurer HM; Gehan EA; Beltangady M; Crist W; Dickman PS; Donaldson SS; Fryer C; Hammond D; Hays DM; Herrmann J
    Cancer; 1993 Mar; 71(5):1904-22. PubMed ID: 8448756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study.
    Walterhouse DO; Lyden ER; Breitfeld PP; Qualman SJ; Wharam MD; Meyer WH
    J Clin Oncol; 2004 Apr; 22(8):1398-403. PubMed ID: 15007087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV, 1978-1997: report from the Children's Oncology Group.
    Raney B; Anderson J; Breneman J; Donaldson SS; Huh W; Maurer H; Michalski J; Qualman S; Ullrich F; Wharam M; Meyer W;
    Pediatr Blood Cancer; 2008 Jul; 51(1):17-22. PubMed ID: 18266224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of dose intensity of vincristine, d-actinomycin, and cyclophosphamide chemotherapy for child and adult rhabdomyosarcoma: a retrospective analysis.
    Kojima Y; Hashimoto K; Ando M; Yonemori K; Yamamoto H; Kodaira M; Yunokawa M; Shimizu C; Tamura K; Hosono A; Makimoto A; Fujiwara Y
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):391-7. PubMed ID: 22806306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of localized nonorbital, nonparameningeal head and neck rhabdomyosarcoma: lessons learned from intergroup rhabdomyosarcoma studies III and IV.
    Pappo AS; Meza JL; Donaldson SS; Wharam MD; Wiener ES; Qualman SJ; Maurer HM; Crist WM
    J Clin Oncol; 2003 Feb; 21(4):638-45. PubMed ID: 12586800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preliminary results of alternating combination chemotherapy (CT) and hyperfractionated radiotherapy (HART) in advanced rhabdomyosarcoma (RMS).
    Mandell LR; Ghavimi F; Exelby P; Fuks Z
    Int J Radiat Oncol Biol Phys; 1988 Jul; 15(1):197-203. PubMed ID: 2455700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide.
    Arndt C; Hawkins D; Anderson JR; Breitfeld P; Womer R; Meyer W
    J Clin Oncol; 2004 May; 22(10):1894-901. PubMed ID: 15143082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The development of VAC chemotherapy in rhabdomyosarcoma: what does one do for an encore?
    Ruymann FB
    Curr Oncol Rep; 2003 Nov; 5(6):505-9. PubMed ID: 14521810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors and surgical treatment guidelines for children with rhabdomyosarcoma of the perineum or anus: a report of Intergroup Rhabdomyosarcoma Studies I through IV, 1972 through 1997.
    Blakely ML; Andrassy RJ; Raney RB; Anderson JR; Wiener ES; Rodeberg DA; Paidas CN; Lobe TE; Crist WM;
    J Pediatr Surg; 2003 Mar; 38(3):347-53. PubMed ID: 12632347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Childhood rhabdomyosarcoma].
    Morikawa Y
    Nihon Geka Gakkai Zasshi; 2005 Jul; 106(7):431-6. PubMed ID: 16045187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Embryonal rhabdomyosarcoma completely resected at diagnosis: The European paediatric Soft tissue sarcoma Study Group RMS2005 experience.
    Bergeron C; Jenney M; De Corti F; Gallego S; Merks H; Glosli H; Ferrari A; Ranchère-Vince D; De Salvo GL; Zanetti I; Chisholm J; Minard-Colin V; Rogers T; Bisogno G;
    Eur J Cancer; 2021 Mar; 146():21-29. PubMed ID: 33567392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome of patients with localized orbital sarcoma who relapsed following treatment on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols-III and -IV, 1984-1997: a report from the Children's Oncology Group.
    Raney B; Huh W; Hawkins D; Hayes-Jordan A; Million L; Rodeberg D; Teot L; Anderson J;
    Pediatr Blood Cancer; 2013 Mar; 60(3):371-6. PubMed ID: 22961750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Studies I to III.
    Wolden SL; Anderson JR; Crist WM; Breneman JC; Wharam MD; Wiener ES; Qualman SJ; Donaldson SS
    J Clin Oncol; 1999 Nov; 17(11):3468-75. PubMed ID: 10550144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group. Childrens Cancer Group, the Pediatric Oncology Group, and the Pediatric Intergroup Statistical Center.
    Ortega JA; Donaldson SS; Ivy SP; Pappo A; Maurer HM
    Cancer; 1997 Jun; 79(12):2435-9. PubMed ID: 9191535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.